Inventiva (NASDAQ:IVA) Shares Gap Up Following Analyst Upgrade

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price gapped up before the market opened on Wednesday after UBS Group upgraded the stock to a strong-buy rating. The stock had previously closed at $4.54, but opened at $4.85. Inventiva shares last traded at $4.8560, with a volume of 235,988 shares.

Several other equities research analysts also recently weighed in on IVA. Wall Street Zen raised shares of Inventiva to a “hold” rating in a report on Saturday, October 18th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Inventiva in a research note on Tuesday, September 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Wednesday, October 8th. Wolfe Research upgraded shares of Inventiva to a “strong-buy” rating in a report on Thursday, November 6th. Finally, Guggenheim cut their price objective on Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Inventiva has a consensus rating of “Buy” and an average target price of $16.57.

Institutional Investors Weigh In On Inventiva

A number of institutional investors have recently bought and sold shares of the business. NewEdge Advisors LLC purchased a new position in Inventiva during the 3rd quarter valued at about $116,000. Millennium Management LLC acquired a new stake in shares of Inventiva during the third quarter worth approximately $649,000. Wealth Enhancement Advisory Services LLC grew its position in Inventiva by 55.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after purchasing an additional 9,212 shares in the last quarter. Finally, Creative Planning acquired a new position in Inventiva in the 2nd quarter valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Price Performance

The business’s 50-day simple moving average is $4.31 and its 200-day simple moving average is $4.45.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.